Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma
About this trial
This is an interventional treatment trial for Endometrial Adenocarcinoma
Eligibility Criteria
Inclusion Criteria: Histologically confirmed endometrial cancer including 1 of the following subtypes: Clear cell carcinoma Serous papillary carcinoma Endometrioid adenocarcinoma Stage III or IV disease Positive adnexa Metastases to serosa, bowel mucosa, abdomen Positive pelvic or paraaortic nodes Positive pelvic washings or vaginal involvement within the radiation port Tumor must be surgically reduced to 2 cm or less within 8 weeks of study entry Must have had a hysterectomy and bilateral salpingo oophorectomy No recurrent disease No distant metastases outside of abdominopelvic area, including: Parenchymal liver metastases Lung metastases Positive inguinal lymph nodes Positive supraclavicular nodes Pleural effusion with malignant cytology Performance status - GOG 0-2 Absolute neutrophil count at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Bilirubin no greater than 1.5 times upper limit of normal (ULN) SGOT and alkaline phosphatase no greater than 3 times ULN Creatinine no greater than ULN Cardiac ejection fraction greater than 50% No other prior or concurrent malignancy within the past 5 years except nonmelanoma skin cancer No prior chemotherapy No prior pelvic or abdominal radiotherapy No prior radiotherapy for other prior malignancy
Sites / Locations
- Gynecologic Oncology Group
Arms of the Study
Arm 1
Experimental
Treatment (doxorubicin, cisplatin, radiation therapy)
Patients receive doxorubicin IV and cisplatin IV on day 1. Treatment repeats every 3 weeks for 3 courses. Patients then undergo whole abdominal radiotherapy 5 days a week for 4-6 weeks.